IL2RA and melanoma: Recombinant IL-2 is approved as a therapy for melanoma but is limited by severe systemic toxicity and the preferential induction of proliferation of Foxp3+ regulatory T cells (Tregs) that express the high-affinity IL2Rα chain CD25 [11].